Also trades as NVS, NOVNEE.SW.
NOVN.SW
Strong BuyFull HouseAI neutralNovartis AG · Healthcare · Switzerland · $271.2B
CHF 116.48 +0.1% · close 5 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Novartis is a focused innovative-medicines company with strong cash generation and a portfolio growing fast enough to offset generic erosion. It has recent positive multiple sclerosis trial data and support for a PMR drug. Against that, a recent study failure knocked the shares, and patent expiries on major products keep the growth bar high. The business is high quality and largely insulated from energy and freight shocks. At a $270B market cap, however, the upside depends on pipeline execution already reflected in consensus rather than on an unpriced shift. Insider selling is negligible.
ABOUT NOVARTIS AG
Read
Novartis AG is a global healthcare company focused on innovative medicines, with a broad portfolio spanning oncology, immunology, cardiovascular, and neuroscience, alongside its generics division Sandoz. The company maintains a strong competitive position through substantial R&D investment, a robust drug pipeline, and extensive global distribution capabilities. Its commitment to pioneering new treatments addresses significant unmet medical needs worldwide.
FINANCIAL SUMMARY (CHF)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.2B | 38.8B | 43.1B | 47.2B | 9.3% | 47.2B | 48.0B | 51.1B | 4.1% |
| EPS (CHF) | 2.66 | 5.95 | 4.93 | 6.00 | 31.2% | 5.57 | 5.91 | 6.57 | 4.7% |
| Shares | 2.1B | 2.0B | 2.0B | 1.9B | -10.0% | 1.9B | — | — | — |
| Debt | 23.2B | 21.9B | 26.0B | 29.4B | 8.2% | 40.8B | — | — | — |
| Equity | 49.4B | 38.8B | 36.7B | 38.4B | -8.1% | — | — | — | — |
| Op CF | 11.9B | 12.0B | 14.7B | 15.9B | 10.4% | 15.3B | — | — | — |
| Inv CF | 1.2B | 4.7B | -6.3B | -4.1B | — | — | — | — | — |
| Fin CF | -17.1B | -11.9B | -9.8B | -12.4B | — | — | — | — | — |
Calmer than 87% of stocks we rank over the past year (23% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NOVN.SW are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NOVN.SW | Novartis AG(you) | $271.2B | 86 | Strong Buy |
| RO.SW | Roche Holding AG | $362.7B | 86 | Strong Buy |
| AMGN | Amgen Inc. | $219.5B | 90 | Strong Buy |
| NOVO-B.CO | Novo Nordisk A/S | $169.7B | 86 | Strong Buy |
| AZN | AstraZeneca PLC | $253.3B | 77 | Buy |
| PFE | Pfizer Inc. | $160.6B | 89 | Strong Buy |
| ABBV | AbbVie Inc. | $468.4B | 89 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $187.7B | 77 | Buy |
| GSK.L | GSK plc | $100.0B | 85 | Strong Buy |
| SAN.PA | Sanofi | $99.7B | 89 | Strong Buy |
Peer medians: ROE 2.5% · P/E 23.6x · Gross margin 53.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.